Everest Collaboration - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Oct. 31, 2023	Sep. 30, 2023	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reimbursement receivable from collaboration			$ 1,312		$ 1,312	$ 1,596
Everest License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement right description		In September 2023, the Company entered into a Collaboration and License Agreement (the “Everest License Agreement”) with Everest pursuant to which, among other things, the Company granted to Everest an exclusive license to develop and commercialize one or more products containing the Company’s proprietary compound, zetomipzomib (the “Products”), in the licensed field in the Greater China region (Mainland China, Taiwan, Hong Kong and Macau), South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam and the Philippines (the “Territory”).
Collaborative agreement upfront payments collected	$ 7,000
Additional milestone payments on achievement	$ 125,500
Reimbursement receivable from collaboration			1,300		1,300
Noncurrent unbilled receivable from collaboration			1,100		1,100
Contra research and development expense			$ 1,600		2,400
Collaboration Revenue | Everest License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue				$ 7,000
Royalty | Everest License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue					0
Development, Regulatory and Commercial Milestones | Everest License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue					$ 0